October 05, 2006 at 10:30 AM EDT
Douglas Lane, President, CEO and Chairman of Genesis Bioventures Featured in Exclusive Interview With WallSt.net

LOS ANGELES, Oct. 5, 2006 (PRIMEZONE) -- Genesis Bioventures, Inc. (OTCBB:GBIW), announced that Douglas Lane, GBIW's President, CEO, and Chairman, was featured in an exclusive interview with WallSt.net. WallSt.net is a professional forum for the financial community, primarily known for interviews with CEOs and prominent business executives.

Topics covered during the interview include the Company's Mammastatin Serum Assay Breast Cancer diagnostic test, the Company's Rapid Mad Cow Assay test and both short and long-term strategic objectives for the Company.

To hear the interview in its entirety, visit www.wallst.net and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.

About Genesis Bioventures, Inc.

Genesis Bioventures, Inc. (GBIW) is a North American-based biomedical corporation focused on facilitating the development and marketing of novel diagnostics, therapeutics and niche products. The Company's immediate development and acquisition efforts are focused on cancer diagnostics, therapeutics and neurodegenerative discoveries within the emerging field of proteomics.

The Company's rapid Mad Cow Test is a 30-minute assay with simple prep that eliminates the economic disincentive current producers have to test all cattle processing: and, more importantly, it creates a substantial economic incentive for wholesalers and retailers to price a 15% to 35% premium for "BSE-Free" beef for an additional a penny a pound cost.

The Company's focus is on the development and marketing of its proprietary Mammastatin Serum Assay Test for breast cancer risk assessment. A recent publication highlighting two studies showed that most women in the studies with low (or no) levels of the protein Mammastatin had breast cancer, while most women in the studies with normal levels of the protein did not have breast cancer.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. These risks and uncertainties include the Company's entry into new commercial businesses, the risk of obtaining financing, recruiting and retaining qualified personnel, and other risks described in the Company's Securities and Exchange Commission filings. The forward-looking statements in this press release speak only as of the date hereof, and the Company disclaims any obligation to provide updates, revisions or amendments to any forward-looking statement to reflect changes in the Company's expectations or future events.

CONTACT: RedChip Companies
         Sanford Diday
         (800) REDCHIP
         Sanford@redchip.com
         info@redchip.com
         www.redchip.com
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here